| Thu, Jul 2, 2009 | | • | Peregrine Pharmaceuticals to Report Fiscal Year 2009 Financial Results
PR Newswire (Thu, Jul 2)
| | Wed, Jul 1, 2009 | | • | Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
PR Newswire (Wed, Jul 1)
| | Tue, Jun 30, 2009 | | • | Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
PR Newswire (Tue, Jun 30)
| | Wed, Jun 24, 2009 | | • | Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
PR Newswire (Wed, Jun 24)
| | Tue, Jun 16, 2009 | | • | Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
PR Newswire (Tue, Jun 16)
| | Wed, Jun 10, 2009 | | • | ASCO Research Foundation Grant Will Support Study of Peregrine's Bavituximab in Lung Cancer
PR Newswire (Wed, Jun 10)
| | Wed, Jun 3, 2009 | | • | Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
PR Newswire (Wed, Jun 3)
| | Mon, Jun 1, 2009 | | • | Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
PR Newswire (Mon, Jun 1)
| | • | Biotech Stocks and the ASCO-Effect
at Seeking Alpha (Mon, Jun 1)
| | Fri, May 29, 2009 | | • | FDA, Clinical Trial Updates: JNJ, INCY, MEDX, CYTX, AGN, PPHM
at Seeking Alpha (Fri, May 29)
| | Thu, May 28, 2009 | | • | Healthy Gains for Cancer Treatment Stocks
Indie Research (Thu, May 28)
| | • | Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
PR Newswire (Thu, May 28)
| | Wed, May 27, 2009 | | • | Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
PR Newswire (Wed, May 27)
| | Mon, May 4, 2009 | | • | Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
PR Newswire (Mon, May 4)
| | Mon, Apr 27, 2009 | | • | Niche antiviral drugmakers rocket on flu news
at MarketWatch (Mon, Apr 27)
| | • | Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
PR Newswire (Mon, Apr 27)
| | Wed, Apr 22, 2009 | | • | Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model
PR Newswire (Wed, Apr 22)
| | Tue, Apr 21, 2009 | | • | Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies
PR Newswire (Tue, Apr 21)
| | Mon, Apr 20, 2009 | | • | Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
PR Newswire (Mon, Apr 20)
| | Fri, Mar 27, 2009 | | • | PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an
EDGAR Online (Fri, Mar 27)
|
Add PPHM News to My Yahoo!:
 
| |
|
0.06% Nasdaq 
0.60%
Headlines
